THE NOVEL PAN-DEACETYLASE INHIBITOR PANOBINOSTAT INDUCES ALTERNATIVE PATHWAYS OF APOPTOSIS IN HEPATOCELLULAR CARCINOMA MODELS

被引：0
|
作者：
Di Fazio, P. [1 ,2 ]
Schneider-Stock, R. [3 ]
Wissniowski, T. [2 ]
Gahr, S. [2 ]
Neureiter, D. [4 ]
Ocker, M. [2 ]
机构：
[1] Univ Palermo, Palermo, Italy
[2] Univ Hosp Erlangen, Erlangen, Germany
[3] Univ Magdeburg, Inst Pathol, D-39106 Magdeburg, Germany
[4] Paracelsus Private Med Univ, Inst Pathol, Salzburg, Austria
来源：
JOURNAL OF HEPATOLOGY | 2009年 / 50卷
关键词：
D O I：
10.1016/S0168-8278(09)60513-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
511
引用
收藏
页码：S190 / S191
页数：2
相关论文
共 50 条
  • [21] Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
    Lu, Yen-Shen
    Kashida, Yoko
    Kulp, Samuel K.
    Wang, Yu-Chieh
    Wang, Dasheng
    Hung, Jui-Hsiang
    Tang, Monica
    Lin, Zhong-Zhe
    Chen, Jung
    Cheng, Ann-Lii
    Chen, Ching-Shih
    HEPATOLOGY, 2007, 46 (04) : 1119 - 1130
  • [22] The novel potent pan-deacetylase (DAC) inhibitor, panobinostat (LBH589), markedly enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
    Campbell, Richard A.
    Sanchez, Eric
    Steinberg, Jeffrey
    Share, Michael
    Wang, Joseph
    Li, Mingjie
    Chen, Haiming
    Shalitin, Dror
    Pang, Shen
    Said, Jonathan
    Berenson, James R.
    BLOOD, 2007, 110 (11) : 743A - 743A
  • [23] Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan-Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.
    Ottmann, Oliver G.
    Spencer, Andrew
    Prince, H. Miles
    Bhalla, Kapil N.
    Fischer, Thomas
    Liu, Angela
    Parker, Kathryn
    Jalaluddin, Muhammad
    Laird, Glen
    Woo, Margaret
    Scott, Jeffrey W.
    DeAngelo, Daniel J.
    BLOOD, 2008, 112 (11) : 352 - 353
  • [24] In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers
    Maschauer, Simone
    Gahr, Susanne
    Gandesiri, Muktheshwar
    Tripal, Philipp
    Schneider-Stock, Regine
    Kuwert, Torsten
    Ocker, Matthias
    Prante, Olaf
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (01) : 27 - 34
  • [25] Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
    Richardson, Paul G.
    Alsina, Melissa
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael
    Mukhopadhyay, Sutapa
    Snodgrass, Susan
    Schlossman, Robert
    BLOOD, 2011, 118 (21) : 370 - 371
  • [26] Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
    Sally Clive
    Margaret M. Woo
    Thomas Nydam
    Lindsay Kelly
    Margaret Squier
    Mark Kagan
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 513 - 522
  • [27] Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines
    Di Fazio, Pietro
    Montalbano, Roberta
    Neureiter, Daniel
    Alinger, Beate
    Schmidt, Ansgar
    Merkel, Anna Lena
    Quint, Karl
    Ocker, Matthias
    EXPERIMENTAL CELL RESEARCH, 2012, 318 (15) : 1832 - 1843
  • [28] Ibulocydine Is a Novel Prodrug Cdk Inhibitor That Effectively Induces Apoptosis in Hepatocellular Carcinoma Cells
    Cho, Seung-Ju
    Kim, Young-Jong
    Surh, Young-Joon
    Kim, B. Moon
    Lee, Seung-Ki
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (22) : 19662 - 19671
  • [29] Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
    Clive, Sally
    Woo, Margaret M.
    Nydam, Thomas
    Kelly, Lindsay
    Squier, Margaret
    Kagan, Mark
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 513 - 522
  • [30] Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)
    Duvic, M.
    Vanaclocha, F.
    Bernengo, M. G.
    Okada, C.
    Breneman, D.
    Zinzani, P. L.
    Zhang, L.
    Bopp, K.
    Laird, G.
    Hirawat, S.
    Prince, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345